RA
OKUR

Rosalind Advisors’s OnKure Therapeutics OKUR Stock Holding History

Rosalind Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84M Sell
443,763
-286,725
-39% -$885K 0.74% 25
2025
Q4 		$2.12M Buy
+730,488
New +$2.19M 0.74% 24

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rosalind Advisors's OKUR Position: Q1 2026 in Review

Rosalind Advisors reduced its OnKure Therapeutics (OKUR) stake by 39% in Q1 2026, selling an estimated $885K and leaving 443,763 shares worth $1.84M. The position accounts for 0.74% of the portfolio, ranked #25.

Rosalind Advisors first reported a position in OKUR in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.12M in Q4 2025. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Rosalind Advisors held 443,763 shares of OnKure Therapeutics worth $1.84M as of Q1 2026.
  • Rosalind Advisors sold 286,725 OnKure Therapeutics shares in Q1 2026, an estimated $885K.
  • OnKure Therapeutics made up 0.74% of Rosalind Advisors's portfolio in Q1 2026, its #25 holding.
  • Rosalind Advisors first reported a position in OnKure Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Rosalind Advisors's OnKure Therapeutics position peaked at $2.12M in Q4 2025.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.